Journal of Crohns & Colitis

Article	Citations
P171 PSC/IBD and IBD have similar type and location of colonic lesions, but Dye ChromoEndoscopy (DCE) increases detection rate compared to White Light Endoscopy (WLE)	685
P601 Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with Propensity Score adjustment: maintenance phase results from the prospective observational R	191
P301 Relapse rates after withdrawal of thiopurines in patients with Inflammatory Bowel Disease	181
P132 An audit of quality of histopathology reporting of colorectal mucosal biopsies for the diagnosis and assessment of Inflammatory Bowel Disease	178
P051 IFNγ-macrophages could mediate EMT in Crohn’s disease through the WNT pathway	147
P513 Treatment persistence in bio-naive patients with long-standing Crohn’s disease treated with first-line biologics: real-life data from a Croatian tertiary center	120
P269 Spaciotemporal machine learning analysis of complete small bowel capsule endoscopy videos for prediction of outcomes in Crohn’s disease	111
OP14 Interpreting genome-wide association studies of Inflammatory Bowel Disease through the lens of single-cell sequencing	105
P719 Identification of differentially expressed genes between AIEC and non-AIEC clinical isolates during in vitro cell infection	91
P352 Occurrence of moderate to severe anaemia and utilization and efficacy of intravenous iron therapies in a nationwide cohort of Inflammatory Bowel Disease patients	88
P454 Evaluation of the nutritional care status in italian centers managing patients affected by inflammatory bowel disease	82
P368 Safety issues of azathioprine in patients with inflammatory bowel disease: clinical experience from a referral center	80
P570 Prevalence and risk factors for intestinal resection in patients with Crohn’s disease in a Greek referral center	71
P708 Ileal involvement defined by Montreal classification in Crohn’s disease is associated with a distinct microbial composition in ileal and colonic mucosa	70
P187 Major Depression in patients with Ulcerative Colitis and its relationship with clinical activity	66
P007 ORMDL proteins shape homeostasis in the intestinal epithelium by regulating endoplasmic reticulum architecture and autophagy	66
P277 Assessment of fatigue as a patient-reported outcome: Correlation with baseline disease activity and therapy response in Inflammatory Bowel Disease	65
Corrigendum to: ECCO CONFER Investigators, Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series	60
Corrigendum to: Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases	54
DOP88 Long-term real-world data of ustekinumab in Crohn’s Disease – the Stockholm ustekinumab study – STOCUSTE	53
P674 Predictors of response to biologics in Crohn’s Diseases: A population-based study from the epi-IIRN	51
P616 Safety of COVID-19 vaccines in patients with IBD	50
P750 Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes: A Real-World Effectiveness Analyses in a National U.S. Cohort of U.S. Military Veterans with Inflammatory Bowel Disease	49
P139 Inflammatory bowel disease and impairment of working life	48
P222 Chronic pain is common in Paediatric Inflammatory Bowel Disease and impacts quality of life	47

OP32 The gut virome-colonizing Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo	46
P833 Cervical cancer risk in newly diagnosed ulcerative colitis: a nationwide population-based study	43
P709 Endoscopic healing and clinical remission after administration of adalimumab to patients with Crohn’s disease of the small intestine	43
P501 Safety of peri-operative biologics in patients with IBD undergoing resective bowel surgery: experiences of a single center cohort	42
P905 Predictive pharmacogenetic risk of pancreatitis in Inflammatory Bowel Disease patients treated with thiopurines: a case-control study from the ENEIDA registry	42
P113 Protein fingerprint biomarkers of collagen remodeling can evaluate fibrogenesis in an in vitro colonic scar-in-a-jar model	41
P127 Inflammatory Bowel Disease-associated colorectal cancers: retrospective cohort study from a tertiary centre surveillance programme over 10 years	41
P310 Smoking is not an independent risk factor for surgery in patients with Crohn’s Disease on biologic therapy	41
P149 Novel capillary blood point-of-care test for adalimumab and infliximab trough levels: Effects of abnormal blood conditions on the test result	41
P294 Assessment of Fatigue and Associated Factors in Patients with Inflammatory Bowel Disease: A Questionnaire-based Study	40
P308 A new endoscopic scoring system corresponding to histological healing using linked color imaging in ulcerative colitis: SOUL study	39
P358 Long-term clinical outcomes of intestinal Behçet’s disease: a 30-year cohort study at a tertiary hospital in South Korea	39
P324 Long-term impact of the COVID-19 pandemic on Inflammatory Bowel Disease healthcare utilization: A two-year nationwide update	38
P130 Comparison of the clinical course of Ulcerative Colitis according to the presence or absence of clinical symptoms at the time of diagnosis	38
OP05 Outcome of induction therapy with vedolizumab in children: Results from the prospective, multi-centre VEDOKIDS study	38
P473 Real world experience with the Crohn’s Disease Exclusion Diet (CDED) in a tertiary IBD clinic	37
P212 The Impact of Crohn’s Disease in Patients with Colorectal Cancer: A Danish Nationwide Cohort Study, 2009-2019	37
P483 Patient-reported quality of life, anxiety, and depression associated with switching originator infliximab to biosimilar	37
P089 Colonic explant lactate concentration and inflammatory protein secretion in ulcerative colitis	37
P0742 Real-world efficacy and safety of Upadacitinib in IBD patients. Preliminary data from the Apulian Network for Inflammatory Bowel Disease (AN-IBD)	36
P0435 Comparative analysis between capsule endoscopy and ileocolonoscopy for activity detection in ileal Crohn’s disease. Preliminary results from the CAPITER study, a multicenter study from the Young	35
Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series	35
P1213 The role of stress in dietary choices and disease outcomes in Inflammatory Bowel Disease	35
DOP053 Efficacy of appendectomy in inducing remission in moderate-to-severe ulcerative colitis: preliminary one year results of a multicentre prospective cohort study (COSTA)	35
P1252 Prevalence, Incidence and Mortality of Pediatric Inflammatory Bowel Disease in Catalonia	34
P1288 The Association of Long-term Night Shift Work and Related Circulating Proteins with Inflammatory Bowel Disease: A Prospective Cohort and Multi-omics Study	34
P0166 Changes in bone mineral density in young patients with inflammatory bowel diseases	34
P1244 Differential impact of appendectomy with appendiceal inflammation versus no inflammation on inflammatory bowel disease risk in a population-based cohort	34
P0003 Differential Effects of JAK Inhibitors on Epithelial-Immune Interaction in Inflammatory Bowel Disease	34
P0279 Assessing patient-reported health status in moderate-to-severe Crohn’s Disease and Ulcerative Colitis: Results from the communicating needs and features of IBD experiences (CONFIDE) survey	34
P0406 Complications after ileal pouch-anal anastomosis in patients with Ulcerative Colitis and primary sclerosing cholangitis	33
P0391 The impact of point of care ultrasound on time to initiating advanced therapy in IBD (GUIDE-IBD): A randomised controlled trial	33
P0089 Infra-red microspectroscopy provides quantitative assessment of fibro-inflammation in Crohn’s disease strictures and predicts post-operative recurrence	31
P0381 Correlation Between Rectal Endoscopic and Histological Involvement and the Prevalence and Severity of Ano-Perineal Lesions in Inflammatory Bowel Disease	31
DOP022 Shared and Distinct Features of the Gut Microbiome in Immune-mediated Inflammatory Diseases: Initial Analysis from the INTEGRATE Cohort Study	31
DOP016 Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term Extension	31
P0453 Intestinal Ultrasound Correlates with Patient-Reported IBD Disability in Ulcerative Colitis: A Step Towards Integrated Monitoring	31
P0483 Assessment of Disease Activity in Pediatric Inflammatory Bowel Disease Using Intestinal Ultrasound: A Comparative Diagnostic Analysis	30
P0346 Pouch Fistulas: Experience From a Tertiary Center	30
P0250 Circulating blood matrix metalloproteinase (MMP)-10 and 12 can accurately predict mucosal healing in Inflammatory Bowel Disease (IBD) in a multi-centred prospective longitudinal cohort study (20	30
DOP057 Early serum and faecal cytokines predict clinical outcomes in Acute Severe Ulcerative Colitis: results from PREDICT-UC	29
P748 Pharmacokinetics, relative bioavailability, and dose proportionality of a tablet formulation of the sphingosine 1-phosphate-1 receptor modulator VTX002 (formerly OPL-002)	29
P0292 CD8+ Cell Dominance in Immune Checkpoint Inhibitor-Induced Colitis and Its Heterogeneity Across Endoscopic Features	29
P0893 Angiopoietin-like Protein 8 (ANGPTL8) in Inflammatory Bowel Disease and Its Response to Anti-TNFα Therapy; A Prospective Multi Center Study	29
P0818 Addressing unmet needs in adult Inflammatory Bowel Disease care	28
P143 Efficacy of the oral tyrosine kinase 2 (TYK2) inhibitor TAK-279 in two preclinical mouse models of colitis	28
Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn’s Disease	28
P623 The effectiveness and tolerability of Crohn’s disease exclusion diet in adult Crohn’s disease patients: a retrospective study	28
P0551 Diagnostic Accuracy of Low-Cost Blood Test Inflammatory Markers in Severe Ulcerative Colitis	28
Navigating Postoperative Management in Crohn’s Disease: Insights from the PORCSE Study	28

P551 Platelet-to-lymphocyte ratio index for non-invasive assessment of endoscopic activity in small bowel Crohn’s disease: application and prospective validation.	28
P0746 Impact of timing of prophylaxis therapy on post-operative endoscopic recurrence in a real-life cohort of patients whit Crohn’s disease	28
DOP026 Porphyromonas gingivalis secreted htpG disrupts TLR4/ PAPSS2-mediated mucin sulfation and aggravates ulcerative colitis	27
DOP03 Unfermented β-fructan fibres can induce gut inflammation and tumorigenesis in select Inflammatory Bowel Disease patients mediated by gut microbiota	27
Serum Metabolites Relate to Mucosal and Transmural Inflammation in Paediatric Crohn Disease	27
DOP74 Comparative effectiveness of vedolizumab and ustekinumab in Crohn’s Disease patients who failed anti-TNF treatment: Interrogating 1019 patients from the UK IBD BioResource	27
Increased Primary Bile Acids with Ileocolonic Resection Impact Ileal Inflammation and Gut Microbiota in Inflammatory Bowel Disease	27
DOP012 Promising effects of IMU-856, an orally available epigenetic modulator of barrier regeneration - biomarker findings from a Phase 1 clinical study	27
Risk Prediction for Complications in Inflammatory Bowel Disease Surgery: External Validation of the American College of Surgeons’ National Surgical Quality Improvement Program Surgical Risk Calculator	27
DOP69 Longitudinal gut microbiome dynamics in relation to disease flares in Inflammatory Bowel Disease, pilot data from the IBD-Tracker study	27
P297 Treatment of patients with complex perianal Crohn’s disease with darvadstrocel: a single-institution real life experience	26
P694 Age is a strong of predictive risk factor for anti-TNF therapy related adverse events in IBD patients	26
DOP115 Exophiala dermatitidis aggravates colitis through the Syk-CARD9 signaling pathway	26
P367 Are patients with Inflammatory Bowel Disease and two or more associated Immune-Mediated Inflammatory Diseases different from those with no or one associated disease?	26
P083 JAK/STAT pathway and IL-6 activity in moderate to severe Ulcerative Colitis	26
P747 Assessment of a microlearning programme for patients with Inflammatory Bowel Disease (The ADEII project) on ansiety/depression status and illness perception	25
P365 Incidental terminal ileitis in asymptomatic patients. Is it Crohn’s disease?	25
P607 Increased rates of fractures and malignancy in elderly onset IBD in Singapore	25
DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort	25
P837 Improving Vaccination Rates in Patients with Inflammatory Bowel Disease: A Single Centre Audit and Quality Improvement Project	24
P906 The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease. A retrospective observational study	24
P1079 Mindfulness-based cognitive therapy to reduce psychological distress in patients with Inflammatory Bowel Disease: first results of a multicentre randomised controlled trial (MindIBD)	24
P996 Clinical Efficacy and Predictive Factors for the Effectiveness of Granulocyte and Monocyte Adsorption Apheresis Therapy for Ulcerative Colitis：A Retrospective Observational Single Center Study	24
P1104 Shifting Surgical Landscape in Crohn's Colitis: Laparoscopic Supremacy and Robotic Upsurge	24
OP14 Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis	24
ECCO Grant Untangling the gut phagosome dynamics of the relapse/remission cycle in ulcerative colitis	24
DOP79 Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort	24
P1144 Forecasting the Future Prevalence of Inflammatory Bowel Disease in Korea through 2048: An Epidemiologic Study Employing Autoregressive Integrated Moving Average Models	24
P1090 Exposure to an inflammatory prenatal environment and the risk of Inflammatory Bowel Disease in the offspring: a population-based cohort study	23
DOP56 Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn's Disease	23
P024 Synergistic effect of phytochemicals combination including ginsenosides and curcumin on recovery from radiation-induced toxicity	23
P162 The Biosimilar Switch: IBD nurse's experience in Our Lady of Lourdes Hospital	23
P250 Geriatric impairments associate with mortality and hospitalisations during follow-up in older IBD outpatients	23
P081 The integration of transcriptomic and microbiomic data links several intestinal bacterial families with key biological functions in the development of postoperative recurrence in Crohn's disease	22
P060 Increased metabolic activity of faecal Sutterella Wadsworthensis at IBD onset is associated with an increased risk of escalation to biologic therapies - Results from the Birimingham Inception Coh	22
P228 Predictors of steroid therapy refractoriness in admitted Acute Severe Ulcerative Colitis patients	22
P360 Prevalence and risk factors for fatigue in patients with inflammatory bowel disease and endoscopic healing	22
P929 Relation between Crohn’s disease phenotype and response to ustekinumab in Stockholm – the STOCUSTE study	21
P771 Comparing obstructive symptoms and dietary restrictions with Crohn's disease stricture severity	21
P346 Assessing Brain Morphology in Functional Gastrointestinal and Inflammatory Bowel Disorders Using Functional Magnetic Resonance Imaging (fMRI)	21
P1237 Development of an algorithm to identify the best donor-recipient match for FMT in IBD patients based on immune system/microbiota interactions	21
P497 Malnutrition in inflammatory bowel disease: a correlation between clinical and nutritional parameters	21
P273 Defining the prognosis of children with Crohn Disease with the support of magnetic resonance enterography: a multi-center multi-reader study	21
P387 Short and long-term outcomes of surgery for inflammatory (uncomplicated) ileocecal Crohn’s disease: multicentric retrospective analysis of 211 patients	21
P732 Lack of concordance between patient-reported, physician-reported and objective criteria-based identification of suboptimal control in IBD patients: IBD PODCAST study results	21
P918 Can we rely on HLA to predict resistance to biological therapy in Inflammatory Bowel Disease patients?	20
Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients	20
Development of the Escalation of Therapy or Intervention (ETI) Calculator for Patients with Ulcerative Colitis Using ePROMs	20
P406 Disease clearance in patients with ulcerative colitis treated with aminosalicylates	20
P926 Improved standards of colonoscopy for Inflammatory Bowel Disease through implementation of key performance measures - A quality improvement initiative	20
P899 Inflammatory Bowel Disease Patients Show More Recognizable Digestive Symptoms of COVID-19: A Questionnaire Study	20
P514 Beyond the First Attempt: A Multi-Centre UK Analysis of Second JAK Inhibitor Use in Ulcerative Colitis	20
Definitions, diagnosis, and management of postoperative recurrence in Crohn’s disease patients with permanent ileostomy—a systematic review and meta-analysis	19
Disruption of Epithelial Barrier Integrity via Altered GILZ/c-Rel/RACK1 Signaling in Inflammatory Bowel Disease	19
Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn’s Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial	19
Decreased Levels of Atmospheric Pollution and Reduced Prevalence of Inflammatory Bowel Diseases in Europe	19
IBD Risk—It Is All in the Family!	19
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies	19
Incidence, Prevalence, Disease Course, and Treatment Strategy of Crohn’s Disease Patients from the Veszprem Cohort, Western Hungary: A Population-based Inception Cohort Study Between 2007 and 2018	19
Early intestinal ultrasound response to biologic and small molecule therapy is accurate to predict treat-to-target endoscopic outcomes in children with ulcerative colitis: results from the prospective	19
Colectomy Rates did not Decrease in Paediatric- and Adult-Onset Ulcerative Colitis During the Biologics Era: A Nationwide Study From the epi-IIRN	19
Results of the Ninth Scientific Workshop of the European Crohn’s and Colitis Organisation (ECCO): Artificial intelligence in IBD surgery: opportunities and limitations	18
Restoring Prostacyclin/PGI2-PTGIR signaling alleviates intestinal fibrosis in Crohn’s disease via fibroblast-specific YAP/TAZ inhibition	18
P393 Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for acute severe colitis	18
DOP15 Intestinal ultrasound correlates with colonoscopy and biomarkers, and can be used in a tight monitoring approach to assess response to therapy in Crohn’s disease: a multicentre prospective study	18
OP28 Children and young adults with inflammatory bowel disease have an increased incidence and risk of developing mental health conditions: a UK population-based cohort study	18
P077 Different granulocyte subsets are involved in the pathogenesis in Crohn’s disease fistula	18
Results of the 9th Scientific Workshop of the European Crohn’s and Colitis Organisation (ECCO): Artificial Intelligence in medical management and precision medicine	18
Video Capsule Endoscopy can Identify Occult Luminal Crohn’s Disease in Patients with Isolated Perianal Fistulas	18
P607 HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease	18
P022 A correlation of serum Fibroblast Growth Factor 21 level with inflammatory markers and indicators of nutritional status in patients with Inflammatory Bowel Disease	18
P307 High frequency of Deep Infiltrating Endometriosis in patients with Inflammatory Bowel Disease: a nested case-control study	18
P720 Exit interviews exploring Crohn’s disease patients’ experience of changes in their bowel urgency during the mirikizumab Phase 3 clinical trial in adult patients with moderate to severe Crohn dise	18
P743 Relative association of bowel urgency improvement versus remission of stool frequency and rectal bleeding with Patient Global Rating of Severity or Change scores in moderately-to-severely active	18
Clostridium perfringens: A Potential Pathobiont in Inflammatory Bowel Disease	18
DOP07 Targeting the canonical WNT signalling pathway as a potential novel therapy in Crohn′s associated fibrosis	18
P329 Stool multiplex molecular PCR assay in comparison to conventional stool tests for detecting gastrointestinal infections as cause of flares in Inflammatory Bowel Disease	18
DOP55 The increasing burden of direct and indirect costs of IBD	17
P569 Can thiopurines prevent crohn’s disease endoscopic postoperative recurrence in at risk patients?	17
P830 Significant racial and ethnic disparities exist in health-care utilization in inflammatory bowel disease: a systematic review and meta-analysis	17

P524 Predictors of immunogenicity in patients with Inflammatory Bowel Disease treated with infliximab: A post hoc analysis of the randomised phase I CT-P13 SC study	17
P518 Partial enteral nutrition use for Crohn’s disease management: a systematic review	17
P041 The upregulation of tissue factor in colonic mesenchymal cells in active ulcerative colitis is associated with severe and resistant to treatment disease, but tofacitinib has not effect on it	17
DOP68 Autophagy induction in the intestinal epithelium protects against inflammation-induced barrier loss in vivo.	17
P094 Impacts of 5-aminosalicylic acid on the intestinal microbiota leading to the anti-inflammatory effect	17
P757 Visceral adiposity and not subcutaneous adiposity or body mass index is more strongly associated with relapse in inflammatory bowel disease	17
P325 Proton pump inhibitors are associated with a disabling course of Crohn’s disease	17
P103 Colitis-associated faecal miRNAs are mediators of host-microbiota interactions and key regulators of intestinal permeability and inflammation	17
P152 The prevalence of Thiopurine-methyltransferase and NUTD15 in patient with ulcerative colitis: a hospital-based study in central Taiwan	17
P810 Association between Ustekinumab Trough Levels, Serum IL-22 and Oncostatin M Levels with Clinical and Biochemical Outcomes in Patients With Crohn’s Disease	17
N31 Nothing about us, without us: Developing a reliable IBD information source on sexual well-being by patients and for patients	17
P030 Assessing dietetic interventions in inflammatory bowel disease patients	17
P687 Durability of recaptured response to ozanimod during the True North open-label extension	16
P0211 Characterization of drug-specific CD4+ T cells in patients with inflammatory bowel diseases	16
DOP104 International differences in pre-operative characteristics and postoperative management in patients with Crohn’s disease following ileocolic resection: a report from the IMPACT consortium	16
P1133 Safety and effectiveness of indigo naturalis for induction of remission in children with mild to moderate ulcerative colitis: a prospective open-label trial	16
P0447 Accurate, rapid and economical diagnosis of chronic enteropathy associated with SLCO2A1 gene and the analysis of its clinical pathological features	16
P0985 Real-world experience of subcutaneous infliximab use in children with inflammatory bowel disease (IBD) at a tertiary paediatric centre	16
P1198 Statin Use for Primary Prevention of Cardiovascular Disease and its Association with Risk of Incident Inflammatory Bowel Disease: A Population-Based Cohort Study	16
DOP063 Hospitalised severe ulcerative colitis patients treated with rescue infliximab risk treatment failure due to underexposure caused by high drug clearance	16
P1144 Effect of baseline disease severity on achieving efficacy endpoints in patients with Ulcerative Colitis treated with filgotinib	16
P1300 HLA-C*06 Genotype and Ustekinumab Therapy Persistence in Inflammatory Bowel Disease	16
P0280 Evaluation of the diagnostic accuracy of trans-perineal ultrasound for predicting rectal histoendoscopic remission in Ulcerative Colitis (The TRINITY Study): A prospective, paired, comparative s	16
P0544 Long-term evaluation of quality of life in inflammatory bowel diseases: results from a prospective cohort study	16
P657 Persistence in smoking cessation in inflammatory bowel disease (IBD)	16
P1123 Baseline characteristics and nutrition in patients with moderately to severely active Inflammatory Bowel Disease: Results from the phase 3 UNITI Jr and UNIFI Jr trials	16
P1199 Early life exposures predict childhood-onset IBD in a population-based cohort	16
DOP008 High clinical and endoscopic remission rate with Vedolizumab in early CD patients: the 2nd interim analysis from a prospective multicenter interventional Study (EARLY CD)	16
P0356 A case of pulmonary nodules in Ulcerative Colitis and primary sclerosing cholangitis: is it drug or disease?	16
P0954 Food-related quality of life and dietary choices are associated with disease activity in patients with inflammatory bowel disease	16
P649 The impact of COVID-19 on quality of life among patients with inflammatory bowel diseases – A Danish prospective population-based cohort study	15
P0965 Sequencing Therapy for Optimal Response in Mirikizumab (STORM) Study	15
P509 Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn’s disease	15
P346 Chronic pouch failure rates after close rectal dissection and total mesorectal excision in ileal pouch-anal anastomosis	15
P0594 Efficacy and safety of etrasimod in Japanese UC patients: results of a phase 2 dose-ranging study	14
P0513 Comparative Evaluation of Clinical Scores for Predicting Response to Systemic Steroid Treatment in Hospitalized Adult Patients with Acute Severe Ulcerative Colitis: A Retrospective Study	14
P465 Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?	14
P0599 Efficacy and safety of intravenous methylprednisolone and hydrocortisone in Acute Severe Ulcerative Colitis (ASUC) – a posthoc analysis of the IASO trial	14
P0590 Long term outcomes of biologic therapy for the treatment of prepouch ileitis: a multi-centre multi-national retrospective study	14
N20 Transcutaneous Electrical Acupuncture-point Stimulation for Depressive symptoms in Inflammatory Bowel Disease: a feasibility study	14
P052 Comparing T cell responses to food antigens in Inflammatory Bowel Disease patients and healthy donors	14
P0395 Endoscopic Approaches for Colorectal Neoplasia Surveillance in Inflammatory Bowel Disease: A Systematic Review and Network Meta-Analysis	14
P0575 Bronchiectasis in patients with inflammatory bowel disease – prevalence, predictors, and clinical characteristics	14
P1270 Drugs associated with Microscopic Colitis: a comprehensive pharmacovigilance analysis	14
P0314 External validation of ultrasound scores for Crohn’s Disease: IBUS-SAS, BUSS, SUS-CD, Simple-US	14
P579 Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s disease	14
P0671 Supporting vedolizumab treatment throughout pregnancy: Insights from a population pharmacokinetic model	14
P0106 Profiling inflammation-associated T helper subsets in Inflammatory Bowel Disease	14
P0142 CD47-SIRPα Contributes to the Microenvironment of Stricturing Crohn's Disease by Mediating the Crosstalk between Macrophages and Stromal cells: “Eat Me” or “Don't Eat Me”	14
P0432 CMV infection in IBD patients with disease flare in the era of advanced therapies and outpatient setting	14
P0798 Forty-eight months outcomes of Teduglutide in adult stable patients with short bowel syndrome and home parental nutrition dependence: a real-world italian single center observational cohort stud	13
P1167 Treatable traits (TTs) approach in the management of Inflammatory Bowel Disease: a new concept	13
Self-care in patients affected with inflammatory bowel disease and Mutuality in nursing: A protocol for a longitudinal study	13
P125 MIG (CXCL9) and IL22 are key biomarkers that discriminates between paediatric IBD patients and non-IBD patients in a novel biomarker model	13
DOP88 Understanding the molecular mechanisms of anti-TNF treatment failure: Whole blood DNA methylation changes associated with primary non-response to anti-TNF treatment in patients with Crohn’s dise	13
P1255 Impact of depression on health related quality of life in Ulcerative Colitis patients-are we doing enough? A single tertiary center experience	13
P1219 Late onset inflammatory bowel disease (IBD): Experience from two tertiary centers in Greece	13
P0466 Impact of the COVID-19 Pandemic on Clinical Presentation and Management of Inflammatory Bowel Disease: A Multicentre Study in the West Midlands, UK	13
Adequacy of disclosures in oral presentations at the 20th Congress of European Crohn’s and Colitis Organisation	13
P0368 Novel endoluminal parameters to predict primary loss of response in patients with Crohn’s disease: a national survey and multi-centre study	13
P0048 Alterations in circulating T-cell subpopulations reflect disease activity in Ulcerative Colitis	13
P1240 Overweight in patients with inflammatory bowel disease and the associated risk of malnutrition	13
P253 Histological Remission and Activity as Predictor of Relapse, Hospitalization, and Surgery in Ulcerative Colitis: Systematic Review and Meta-analysis	13
P161 The use of Novel Natural Treatments for Inflammatory Bowel Diseases	13
Artificial Intelligence-assisted Video Colonoscopy for Disease Monitoring of Ulcerative Colitis: A Prospective Study	12
OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 study	12
P396 Ustekinumab Is A Promising Option For The Treatment Of Postoperative Recurrence Of Crohn’s Disease	12
P738 Response to etrasimod treatment in ulcerative colitis is associated with a reduction of circulating B and pro-inflammatory T cells: a single-cell-based post-hoc sub-analysis of the ELEVATE UC 52	12
Avoidant/Restrictive Food Intake Disorder Symptoms Are Not as Frequent as Other Eating Disorder Symptoms When Ulcerative Colitis Is in Remission	12
Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study	12
P329 Which should come first? Surgery or biologic therapy for ileocaecal Crohn’s disease in biologic naïve patients	12
DOP05 Bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn´s Disease	12
Development and Validation of the Glasgow Exclusive Enteral Nutrition Index of Compliance	12
ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease	12
P865 Anxiety and Depression is Associated with Poor Sleep Quality in patients with Inflammatory Bowel Disease (IBD)	12
OP40 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Crohn’s disease: result	12
P623 Network meta-analysis to evaluate the comparative efficacy of advanced therapies as first line for maintenance treatment of adult patients with moderate-to-severe Crohn’s disease	12
Three-dimensional Pouchography: A Proof-of-concept Study of a Breakthrough Technique for Visualising Ileoanal Pouch Anatomy and Morphology in Normal and Mechanical Pouch Complication Patients	12
P507 United States and European patient perspectives on the impact of moderate-to-severe Ulcerative Colitis on sexual activity: Communicating Needs and Features of IBD Experiences (CONFIDE) survey	12
OP01 Withdrawal of infliximab or anti-metabolite therapy in Crohn’s Disease patients in sustained remission on combination therapy: A randomized unblinded controlled trial (SPARE)	12
DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).	12
Differences in Healthcare Utilization in Women with and without Inflammatory Bowel Diseases During Preconception, Pregnancy and Postpartum: A Population-Based Cohort Study	12
P388 Eliakim score performance among patients with active Crohn’s disease	12
P006 Engineered propionate-producing bacteria attenuates murine colitis by modulating the immune function of resident macrophages via histone deacetylase	12
P512 Early proactive therapeutic drug monitoring with ustekinumab therapy in paediatric Crohn's Disease	12
Endoscopic Lesions of Postoperative Anastomotic Area in Patients With Crohn’s Disease in the Biologic Era: A Japanese Multi-Centre Nationwide Cohort Study	12
Evolution of IL-23 Blockade in Inflammatory Bowel Disease	12
P879 Clinical significance of plasma interleukin-22 as a biomarker of inflammation in patients with Crohn’s disease and ulcerative colitis	12
P649 Long-term follow-up of the PROTDILAT study; LONG-PROTDILAT Prospective multicenter randomized comparative study of endoscopic treatment of strictures in Crohn's disease (CD): self-expandable meta	11
P084 Natural extracts and omega-3 derived molecule: role in resolution of intestinal inflammation	11
P585 Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure	11
P592 Higher predictive power of epigenetic signatures for response to vedolizumab and ustekinumab in anti-TNF naïve patients with active Crohn’s disease	11
P336 Exploring Extracellular Matrix Markers in Ulcerative Colitis: Degradation and Formation Insights	11
P867 Abdominally targeted yoga-based physical exercises as a therapeutic intervention for Inflammatory Bowel Diseases	11
P349 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Descriptive Comparison of Experiences of Bowel Urgency among Patients with Ulcerative Colitis in Canada, Europe, and the US	11